ValuEngine lowered shares of BIOLASE Inc (NASDAQ:BIOL) from a hold rating to a sell rating in a report released on Monday, July 24th.
Separately, Singular Research started coverage on shares of BIOLASE in a report on Tuesday, April 25th. They set a buy rating and a $2.50 target price for the company.
BIOLASE (BIOL) traded up 15.77% on Monday, reaching $0.66. 111,669 shares of the company traded hands. BIOLASE has a 1-year low of $0.48 and a 1-year high of $1.98. The stock’s 50-day moving average is $0.84 and its 200-day moving average is $1.19. The stock’s market capitalization is $50.14 million.
BIOLASE (NASDAQ:BIOL) last announced its earnings results on Monday, August 7th. The medical technology company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by $0.04. BIOLASE had a negative net margin of 34.01% and a negative return on equity of 151.86%. The business had revenue of $12.61 million for the quarter. Equities research analysts expect that BIOLASE will post ($0.15) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2017/08/14/biolase-inc-nasdaqbiol-downgraded-by-valuengine-updated-updated.html.
A hedge fund recently raised its stake in BIOLASE stock. Trellus Management Company LLC boosted its position in BIOLASE Inc (NASDAQ:BIOL) by 20.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 350,857 shares of the medical technology company’s stock after buying an additional 59,104 shares during the period. Trellus Management Company LLC owned approximately 0.52% of BIOLASE worth $340,000 as of its most recent SEC filing. 37.55% of the stock is currently owned by institutional investors.
BIOLASE Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BIOLASE Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE Inc and related companies with MarketBeat.com's FREE daily email newsletter.
